XOMA Corporation (Nasdaq: XOMA) combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. XOMA's world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government and has licensed certain of its fundamental technologies to more than 60 companies.
In 2010, XOMA partnered with Les Laboratoires Servier (Servier), France's leading independent pharmaceutical company, for the development of XOMA’s lead product gevokizumab (IL-1 beta modulating antibody). This collaboration brings together Servier's resources and expertise in pharmaceutical product development and commercialization with XOMA's expertise in biologics clinical development and manufacturing capabilities.
Today, XOMA's principal activities are centered on the advancement of gevokizumab, its preclinical pipeline and its biodefense business.
XOMA's antibody technology platforms include an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, Bacterial Cell Expression (BCE), affinity maturation and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. Overall, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are currently in clinical development. XOMA is entitled to development-related milestones and royalties on antibodies covered under these licenses.
May 23, 2013 at 9:00 AM PT
Annual Shareholder Meeting
May 10, 2013 at 8:30 AM ET
Credit Suisse 2013 Antibody Day